TA-7552
(Synonyms: 二甲基4-(3,4-二甲氧苯基)-1-羟基-5,6,7-三甲氧基萘-2,3-二甲酸基酯) 目录号 : GC32609
TA-7552是一种有效的胆固醇降低剂。
Cas No.:104756-72-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
TA-7552 is a potent cholesterol-lowering agent.
TA-7552 is a potent cholesterol-lowering agent. When TA-7552 is mixed with unsupplemented CLEA CE-2 powder in a concentration of 0.05% and administered to rats for 7 days, TA-7552 does not reduce the normal level of serum cholesterol. The hypocholesterolemic effect of TA-7552 is apparent at the lowest concentration (0.01%) of the drug in the diet, corresponding to a daily dose of ~10 mg/kg body weight, and maximal at the highest concentration of 0.2% TA-7552, lowering serum total cholesterol by 72% while elevating serum HDL cholesterol by 88%. TA-7552 also dose dependently suppresses this rise of hepatic cholesterol, and its lowering rate at the maximal dose is 90%[1].
[1]. Takashima K, et al. The hypocholesterolemic action of TA-7552 and its effects on cholesterol metabolism in the rat. Atherosclerosis. 1994 Jun;107(2):247-57.
Animal experiment: | Male Sprague-Dawley rats (4 weeks of age) are used in this experiment. In the mechanism study, rats are divided into two or three groups of 4 to 6 animals so that the mean body weight, which varies from 210 g to 330 g, is similar between the groups. The experimental groups are treated with TA-7552 (0.1% in CE-2 powder) or cholestyramine (5% in CE-2 powder) by feeding the diet ad libitum for a period of time; The control groups are fed CE-2 powder. When the feces are collected, the animals are individually housed in a metabolic cage, and the collected feces are lyophylized and stored at -20°C[1]. |
References: [1]. Takashima K, et al. The hypocholesterolemic action of TA-7552 and its effects on cholesterol metabolism in the rat. Atherosclerosis. 1994 Jun;107(2):247-57. | |
| Cas No. | 104756-72-1 | SDF | |
| 别名 | 二甲基4-(3,4-二甲氧苯基)-1-羟基-5,6,7-三甲氧基萘-2,3-二甲酸基酯 | ||
| Canonical SMILES | O=C(C1=C(C(OC)=O)C(C2=CC=C(OC)C(OC)=C2)=C3C(OC)=C(OC)C(OC)=CC3=C1O)OC | ||
| 分子式 | C25H26O10 | 分子量 | 486.47 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0556 mL | 10.2781 mL | 20.5563 mL |
| 5 mM | 0.4111 mL | 2.0556 mL | 4.1113 mL |
| 10 mM | 0.2056 mL | 1.0278 mL | 2.0556 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet